SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

The rally toward fresh highs is drawing attention ahead of the expected Q3 report, with traders weighing BRIUMVIs growth against unconfirmed buyout speculation and possible short-covering. Some see the move as a bet on earnings and the companys commercial prospects rather than an acquisition; no deal has been confirmed.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its prespecified 80th death event has triggered final analysis, with topline results expected this quarter. Traders are divided over whether GPS improved survival: bullish holders see the pending readout as a major catalyst, while bears question the efficacy case, and the share-price decline has intensified debate about selling pressure and alleged short activity.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal suspension have fueled Bitcoin selling and concerns about crypto exchange security. Traders disagree over whether the incident signals broader risk or is isolated to Binance, with some viewing the pullback as a buying opportunity and others warning of further downside.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens PAPZIMEOS commercial launch and stronger-than-expected quarterly results, including a move to profitability, are driving bullish discussion about its growth prospects. Traders also debate whether potential INO-3107 competition could challenge PAPZIMEOS and whether heavy short interest is amplifying the stocks moves.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader technology and semiconductor selloff as traders question whether massive AI infrastructure spending will generate adequate returns, with mixed Amazon and Intel results adding to sector concerns. The community is split between warnings that the AI trade may be overstretched and dip buyers who view the decline as a temporary pullback while AI demand remains strong.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

A strong third-quarter earnings beat, supported by growth in Eylea HD and Sanofi collaboration revenue tied to Dupixent, has driven a sharp move higher in REGN. Traders are broadly cheering the results and breakout, while some are watching for a pullback after the rally.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The decline appears tied to trader concerns that newly tradable shares from the merger will expand the float, alongside broader weakness in small-cap and technology stocks. The share-supply claims are unverified in the available reporting.

Critical Metals’ Merger Gets Strong Backing From European Lithium Shareholders – Here’s What Comes Next

Equity

Under the proposed all-stock transaction, Critical Metals will acquire 100% of European Lithium’s issued shares and listed options


GLND, GRML, CRML Stocks Surge Premarket: Trump Announces ‘Massive’ Oil, Gas And Mineral Exploration Plans In Greenland

In a Truth Social post, U.S. President Donald Trump said experts believe Greenland could hold some of the world’s largest easily accessible oil reserves.


Nasdaq 100 Hits Record Highs As Investors Shrug Off Pressure From Soaring Yields — NVDA, SPCX, CRML, TSLA, QCOM In Focus

The ISM report showed that the Purchasing Managers' Index for services came in at 54.9% in September, roughly in line with expectations.


CRML Stock Set To Snap Six-Session Losing Streak After Critical Metals Secures Tanbreez Approval – CRML Bulls Eye 175% Upside

Greenland approved the Mining Plan and Closure Plan for its Tanbreez rare-earth project till 2050.


Tungsten Has Tripled in 2026 as U.S. Explorers Race to Drill

Tungsten Has Tripled in 2026 as U.S. Explorers Race to Drill Tungsten Has Tripled in 2026 as U.S. Explorers Race to DrillPR NewswireVANCOUVER, BC, Oct. 1, 2026VANCOUVER, BC, Oct. 1, 2026 /PRNewswire/ -- U.S. Metal NewsNews Commentary - The global tungsten market is projected to grow from...

Texas Emerges as a Hub for America's Rare Earth Supply Chain

Texas Emerges as a Hub for America's Rare Earth Supply Chain Texas Emerges as a Hub for America's Rare Earth Supply ChainPR NewswireDALLAS, Sept. 29, 2026 DALLAS, Sept. 29, 2026 /PRNewswire/ -- American News Group News Commentary- The global rare earth magnets market is projected to grow from...

Critical Minerals Wrap: CRML, GRML Surge On Greenland Deal, US Stockpile Push Accelerates As Trump-Xi Talks Put Rare Earths In Spotlight

A flurry of developments reshaped the critical-minerals landscape this week, with Greenland projects attracting fresh attention.

Greenland Mining Company Plans To Double Size Of Rare-Earth Mine As US Signs Agreement

Greenland Mining Company Plans To Double Size Of Rare-Earth Mine As US Signs Agreement

 Authored by Jill McLaughlin via The Epoch Times,

Days after President Donald Trump announced a security agreement with Greenland and Denmark, Greenland Mines applied on Sept. 21 to double the size...

Why Is GRML Stock Surging In Pre-Market Today?

Greenland Mines secured more than $42 million in funding and ended its ATM program.


Trump, Greenland Deal Sparks CRML Trading Frenzy: These ETFs Rocket 75%

Critical Metals surged 38% after the Trump-Greenland deal, sending these ETFs to the top gainers list with gains of over 75%.read more...

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Critical Metals will add European Lithium’s remaining 7.5% stake in the Tanbreez project to its existing holding.</li><li>The deal now requires approval from the Supreme Court of Western Australia.</li><li>The merger is expected to become effective on October 27, with completion scheduled for November 5.</li></ul>Critical Metals (CRML) was in the spotlight on Thursday after the Greenland-based rare-earth miner moved a step closer to acquiring European Lithium and consolidating its critical minerals assets.The proposed merger received overwhelming support from European Lithium’s shareholders and optionholders. About 99.96% of shareholder votes cast were in favour, while all participating optionholders also voted in favour of the merger.Despite the update, <a class="mention" data-mention="$CRML" data-symbol-id="CRML" href="https://stocktwits.com/symbol/CRML" target="_blank">CRML shares</a> were down 6% at the time of writing, tracking weakness in the broader metals and mining market. The VanEck Rare Earth and Strategic Metals ETF (REMX) was down 3.7%.<h2 class="st-heading-2">Why CRML Is Acquiring European Lithium</h2>Under the proposed all-stock transaction, Critical Metals will acquire 100% of European Lithium’s issued shares and listed options. European Lithium shareholders will receive 0.045 CRML shares for every share held.If the acquisition goes through, Critical Metals will gain full ownership of the Tanbreez rare earth project, adding European Lithium’s remaining 7.5% stake to its existing holding.In a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/TonySage7237/status/2113195436718571655">post</a> on X, CEO Tony Sage said CRML will not require any new equity for a “long period of time.” “We will concentrate our focus solely on Tanbreez,” he added.<h2 class="st-heading-2">What’s Next?</h2>The deal now requires approval from the Supreme Court of Western Australia, with a final hearing scheduled for October 26. If approved, the merger is expected to become effective on October 27, with completion scheduled for November 5.Post the merger, newly issued Critical Metals shares will begin trading on Nasdaq on November 6, with European Lithium expected to be delisted from the Australian Securities Exchange.<h2 class="st-heading-2">Retail Remains Bearish On CRML</h2>Retail sentiment surrounding CRML on Stocktwits remained ‘bearish’ over the past 24 hours.<img src="https://news.stocktwits-cdn.com/CRML_2de2d03b9e.png" alt="CRML.png">The stock has shed more than 23% so far this year. In comparison, REMX is down 33%.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bhvn-stock-eyes-biggest-single-day-gain-in-4-years-after-fda-approval-for-vyglxia/cZxwBVkRBwU">BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Rare-earth mine in Baiyun'ebo or Bayan Obo. Baiyun'ebo or Bayan Obo is a mining town in Inner Mongolia in China.

Critical Metals will add European Lithium’s remaining 7.5% stake in the Tanbreez project to its existing holding.

VanEck Rare Earth and Strategic Metals ETF

$ALAB

$WULF

$CRML

$ALAB, $TE, $WULF, and $CRML are pulling back hard today. Which are you most interested in buying right now?

Which pullback are you most interested in buying - $ALAB, $TE, $WULF, or $CRML?

Stocktwits

Astera Labs Inc

T1 Energy Inc.

TeraWulf Inc

Which pullback are you most interested in buying - 

Current Price	$7.16
Prev Close	$7.95
Open	$7.50
Dividend Yield	0.00%
50-Day Moving Average	$7.14
Beta	1.95
Avg. Volume	9.86M
PE Ratio	-4.26

52-Week High	$21.86
52-Week Low	$5.12
Market Capitalization	$1.17B
EPS (Annual)	-$1.87
Price to Book	3.39
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

CRML Fundamentals